What are TRK inhibitors?
TRK inhibitors are targeted cancer medicines that block abnormal proteins called TRK fusion proteins. The two first drugs of this kind are larotrectinib and entrectinib. Both are taken by mouth as capsules or liquid.
They work only in cancers that carry a specific genetic change called an NTRK gene fusion. This change can occur in many different types of cancer, in both children and adults. For this reason, TRK inhibitors were among the first cancer medicines approved based on a gene change rather than the organ where the cancer started. This is known as a tumour-agnostic or site-agnostic approval.
NTRK fusions are rare in common cancers, usually found in well under 1% of cases. In a few rare cancers, however, they are found in most tumours. For people whose cancer has this change, TRK inhibitors can shrink the cancer dramatically, often with mild side effects.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of treatment | Targeted therapy (kinase inhibitor) |
| Drugs | Larotrectinib, entrectinib; newer drugs such as repotrectinib |
| Main use | Advanced solid tumours with an NTRK gene fusion |
| Test needed | Tumour testing for NTRK fusion |
| How it is given | Capsules or oral liquid, at home |
| Dosing | Larotrectinib twice daily; entrectinib once daily |
| Course length | Continued for as long as it works and is tolerated |
| Common side effects | Dizziness, tiredness, weight gain, changes in taste, constipation, raised liver enzymes |
A short history
NTRK fusions were first described in a bowel cancer sample in the 1980s, but for decades there was no way to target them. Larotrectinib was designed specifically to block TRK proteins, while entrectinib was developed to block TRK, ROS1 and ALK. Both received their first approvals in 2018 and 2019, after early trials showed striking responses in children and adults with many different cancers.
2. How it works
The TRK family
TRK proteins (TRKA, TRKB and TRKC) are receptors on nerve cells. They help nerves grow, survive and send signals, and they play a role in pain, appetite and balance. They are made by three genes called NTRK1, NTRK2 and NTRK3.
What goes wrong in cancer
In an NTRK fusion, part of an NTRK gene breaks off and joins to an unrelated gene. The resulting fusion protein is switched on all the time, sending constant “grow and divide” signals inside the cell. The cancer becomes heavily dependent on this signal.
| Step | Effect |
|---|---|
| 1. Gene fusion | Part of an NTRK gene joins another gene |
| 2. Abnormal protein | The fusion protein is always active |
| 3. Constant signals | Growth pathways inside the cell stay switched on |
| 4. TRK inhibitor | The drug fits into the active pocket of the TRK kinase and blocks it |
| 5. Result | Growth signals stop and the cancer often shrinks |
Larotrectinib and entrectinib compared
| Feature | Larotrectinib | Entrectinib |
|---|---|---|
| Targets | TRKA, TRKB, TRKC only | TRKA, TRKB, TRKC, plus ROS1 and ALK |
| Dosing | Twice daily | Once daily |
| Age | Children from birth and adults | Children over 1 month in some regions and adults |
| Brain activity | Some activity in the brain | Designed to cross into the brain; good activity in brain metastases |
| Other uses | NTRK fusion cancers | Also used for ROS1-positive lung cancer |
3. Who it is for
TRK inhibitors are used for people whose cancer has an NTRK fusion, usually when the cancer is advanced, cannot be removed safely, or would need surgery that causes serious harm.
Conditions treated
| Condition | How often NTRK fusions occur |
|---|---|
| Infantile fibrosarcoma | Most tumours, usually ETV6-NTRK3 |
| Congenital mesoblastic nephroma | Common in the cellular type |
| Secretory carcinoma of the salivary gland | Most tumours |
| Secretory carcinoma of the breast | Most tumours |
| Papillary thyroid carcinoma | A small proportion, higher in children and after radiation |
| Soft tissue sarcoma | A small proportion of some types |
| Lung adenocarcinoma | Rare |
| Colorectal adenocarcinoma | Rare, mainly in mismatch repair-deficient tumours |
| Glioblastoma | Rare; more frequent in infant brain tumours |
Testing for NTRK fusions
| Test | What it does |
|---|---|
| Immunohistochemistry (IHC) | Screens tumour tissue for TRK protein; a positive result needs confirming |
| RNA-based next-generation sequencing | Most reliable way to detect fusions |
| DNA-based sequencing panels | Detect many fusions, but may miss some |
| FISH | Looks for breaks in a specific gene, often ETV6 |
| Liquid biopsy | Searches blood for tumour DNA; a negative result does not rule out a fusion |
Ask your team whether your tumour has had comprehensive genetic testing, especially if you have an advanced cancer with limited treatment options.
Why tumour-agnostic approval matters
Traditionally, cancer drugs were tested and approved one cancer type at a time, such as breast cancer or bowel cancer. With rare gene changes like NTRK fusions, it would be almost impossible to run a separate large trial for every tumour type. Instead, the TRK inhibitor trials enrolled people with many different cancers that shared the same fusion. The consistent responses across cancers convinced regulators that the gene change itself was the right target.
This approach has since been used for other medicines. It also means that genetic testing of the tumour has become an important step for many people with advanced cancer, regardless of where the cancer began.
4. Before treatment
| Step | Why it is done |
|---|---|
| Confirm NTRK fusion | The drugs only work in cancers with the fusion |
| Blood tests | Check liver function, blood counts and uric acid |
| Heart tracing (ECG) | Entrectinib can affect heart rhythm |
| Medicines review | Some medicines and grapefruit interact with these drugs |
| Weight | Baseline, as weight gain is common |
| Pregnancy test | These drugs may harm an unborn baby |
| Baseline scans | To measure response later |
5. What to expect: step by step
| Step | What happens |
|---|---|
| 1. Prescription | Your specialist prescribes the drug and dose, based on body size for children |
| 2. Collecting the medicine | Usually from a hospital pharmacy |
| 3. Starting at home | Swallow capsules whole, or measure the liquid with an oral syringe |
| 4. Regular timing | Take at the same times each day, with or without food as advised |
| 5. Early review | Clinic visit and blood tests after 2-4 weeks |
| 6. Scans | Usually every 2-3 months to check response |
| 7. Ongoing monitoring | Blood tests, weight checks and symptom reviews |
| 8. Dose adjustments | The dose may be lowered or paused for side effects |
Before surgery in children
In some children with infantile fibrosarcoma or other NTRK-driven tumours, a TRK inhibitor is given before surgery to shrink the tumour. This can make an operation much smaller, avoiding amputation or the loss of important structures.
6. Side effects and risks
TRK inhibitors are usually well tolerated. Some side effects arise because TRK proteins also work in normal nerves; these are called on-target effects. A review described dizziness, weight gain and pain on stopping the drug as typical on-target effects (Harada and Drilon, 2022).
| Side effect | How common | Notes |
|---|---|---|
| Dizziness and unsteadiness | Common | Take care with driving and heights |
| Tiredness | Common | Often mild |
| Weight gain | Common | TRK signals help control appetite |
| Taste changes | Common, especially with entrectinib | Usually mild |
| Constipation or diarrhoea | Common | Managed with diet and medicines |
| Raised liver enzymes | Common | Monitored with blood tests |
| Anaemia and low white cells | Occasional | Blood tests |
| Tingling or numbness | Occasional | Report to your team |
| Pain when stopping | Possible | Called withdrawal pain; can be managed by tapering |
| Bone fractures | Uncommon | Reported particularly in children |
| Heart rhythm changes | Rare, with entrectinib | ECG monitoring |
| Memory or mood changes | Occasional, with entrectinib | Report changes in thinking or mood |
7. Results and outlook
| Study | Main finding |
|---|---|
| Larotrectinib pooled analysis (159 children and adults) | 79% of evaluable patients had their tumours shrink, and 16% had a complete response; serious drug-related side effects were uncommon (Hong et al., 2020) |
| Entrectinib integrated analysis (54 adults) | 57% had their tumours shrink, across ten tumour types (Doebele et al., 2020) |
| Entrectinib updated analysis (121 adults) | About 61% responded; median response lasted 20 months, and brain metastases shrank in about two-thirds of those measured (Demetri et al., 2022) |
These response rates are very high for medicines given across many cancer types. Responses are often seen within the first two months, and many last for years.
Resistance
Over time, some cancers develop new mutations in the TRK kinase that stop the drug binding. Next-generation drugs such as repotrectinib and selitrectinib were designed to overcome some of these changes (Harada and Drilon, 2022). If your cancer grows on treatment, a new biopsy or blood test may show why and guide the next step.
8. Recovery and aftercare
Living with long-term treatment
Because TRK inhibitors are often taken for many months or years, managing everyday side effects matters.
| Issue | Practical tips |
|---|---|
| Dizziness | Stand up slowly; avoid driving if you feel unsteady |
| Weight gain | Regular activity and support from a dietitian |
| Taste changes | Try different flavours and textures |
| Missed doses | Follow the instructions in the patient leaflet; do not double up |
| Other medicines | Always check with a pharmacist before starting new ones |
| Travel | Carry enough medicine and a letter from your team |
Follow-up
| Check | Typical timing |
|---|---|
| Clinic review | Every 4-12 weeks |
| Blood tests | At each review |
| Scans | Every 2-3 months at first |
| Growth and development in children | Regularly |
Pregnancy and contraception
TRK inhibitors may harm an unborn baby. Use effective contraception during treatment and for the time advised afterwards, and tell your team straight away if you or your partner become pregnant.
Stopping treatment
In some children whose tumour has disappeared, doctors may consider stopping treatment after a period of time and watching closely. If the cancer returns, the same drug often works again. Adults usually continue as long as the drug is working.
Coping with a rare diagnosis
Learning that your cancer has a rare gene change can feel both hopeful and confusing. You may meet doctors who have treated only a few people with the same fusion. Asking for referral to a specialist centre, a molecular tumour board or a clinical trials unit can help ensure that you receive the most up-to-date options. Patient groups focused on rare cancers and precision medicine can also offer support and information.
9. Alternatives
| Alternative | When it is considered |
|---|---|
| Surgery | When the tumour can be removed without major harm |
| Chemotherapy | Standard treatments for the specific cancer type |
| Radiotherapy | Local control of a tumour |
| Other targeted drugs | When a different driver change is found |
| Immunotherapy | Some cancers, such as mismatch repair-deficient colorectal cancer |
| Clinical trials | Next-generation TRK inhibitors after resistance |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Will this drug work for my cancer? | Only if your tumour has an NTRK fusion |
| Is it chemotherapy? | No; it is a targeted drug that blocks a specific protein |
| Will I lose my hair? | Hair loss is not typical |
| Can children take it? | Yes; liquid forms and weight-based doses are available |
| How quickly does it work? | Many people respond within the first one to two months |
| Can I take it with food? | Follow the instructions for your specific drug |
| What if it stops working? | Your team may test for resistance mutations and consider a next-generation drug |
11. Questions to ask your care team
- Has my tumour been tested for NTRK fusions?
- Which TRK inhibitor do you recommend, and why?
- How will we know if it is working?
- What side effects should I report straight away?
- Do any of my other medicines interact with it?
- How long will I need to take it?
- What happens if the cancer becomes resistant?
Resources
- Demetri, G.D. et al. (2022) ‘Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors’, Clinical Cancer Research, 28(7), pp. 1302-1312.
- Doebele, R.C. et al. (2020) ‘Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials’, The Lancet Oncology, 21(2), pp. 271-282.
- Harada, G. and Drilon, A. (2022) ‘TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults’, Cancer Genetics, 264-265, pp. 33-39.
- Hong, D.S. et al. (2020) ‘Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials’, The Lancet Oncology, 21(4), pp. 531-540.
- National Cancer Institute (2026) Larotrectinib Sulfate. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/larotrectinibsulfate (Accessed: October 2026).
- National Cancer Institute (2026) Entrectinib. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/entrectinib (Accessed: October 2026).
Prepared by the editorial team, October 2026.